Literature DB >> 3458832

Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations.

T B Nutman, K D Miller, M Mulligan, E A Ottesen.   

Abstract

Loiasis in residents of endemic areas is generally manifested by microfilaremia, episodic angioedema, periocular migration of adult worms, modest eosinophilia, and variable antibody levels. In 20 temporary residents who acquired loiasis in West Africa, however, the clinical presentations were markedly different. Only three of the 20 had detectable microfilaremia. Furthermore, these patients often showed a state of marked immunological hyperresponsiveness manifested by very high titers of antibody to filariae, increased levels of serum IgE, and profound hypereosinophilia--to levels greater than 3,000/mm3 in 18 of the 20. These patients were also notable for the increased severity, frequency, and pruritic nature of their angioedema. Also, significant complications occurred in seven of the 20; one patient developed endomyocardial fibrosis and six, renal disease after treatment with diethylcarbamazine. Thirteen of the 20 developed subcutaneous nodules; adult parasites were recovered from three of five of these patients who underwent biopsy. All of the patients responded to therapy with diminution of their clinical symptoms and decreases in levels of eosinophils, IgE, and antibody to filariae.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458832     DOI: 10.1093/infdis/154.1.10

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Transient facial swellings in a patient with a remote African travel history.

Authors:  Eugene T Richardson; Robert Luo; Doran L Fink; Thomas B Nutman; John K Geisse; Michele Barry
Journal:  J Travel Med       Date:  2012 May-Jun       Impact factor: 8.490

Review 2.  Therapeutic approaches to patients with hypereosinophilic syndromes.

Authors:  Hans-Uwe Simon; Amy Klion
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

3.  Differences in the Clinical and Laboratory Features of Imported Onchocerciasis in Endemic Individuals and Temporary Residents.

Authors:  Adrienne J Showler; Joseph Kubofcik; Alessandra Ricciardi; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

4.  Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans.

Authors:  C L King; E A Ottesen; T B Nutman
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  IL-10 and its related superfamily members IL-19 and IL-24 provide parallel/redundant immune-modulation in Loa loa infection.

Authors:  Alessandra Ricciardi; Thomas B Nutman
Journal:  J Infect Dis       Date:  2020-06-19       Impact factor: 5.226

6.  Clinical Features of Imported Loiasis: A Case Series from the Hospital for Tropical Diseases, London.

Authors:  Makoto Saito; Margaret Armstrong; Samuel Boadi; Patricia Lowe; Peter L Chiodini; Tom Doherty
Journal:  Am J Trop Med Hyg       Date:  2015-06-22       Impact factor: 2.345

7.  Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to Loa-endemic areas.

Authors:  Jesica A Herrick; Simon Metenou; Michelle A Makiya; Cheryl A Taylar-Williams; Melissa A Law; Amy D Klion; Thomas B Nutman
Journal:  Clin Infect Dis       Date:  2014-09-18       Impact factor: 9.079

Review 8.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

Review 9.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2009-08-19       Impact factor: 22.113

10.  A 41-year-old woman from Cameroon with infertility.

Authors:  Larry W Chang; Megan E Reller; Justin A Bishop; Kawsar Talaat; Thomas B Nutman; Paul G Auwaerter
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.